Companies › Cook MyoSite
1 active drug program in 2 registered trials: 2 Phase 3; Gastroenterology, Genitourinary; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AMDC-USR (iltamiocel) Autologous muscle-derived cells injected into urinary sphincter | – | Phase 3 | Stress Urinary Incontinence; Fecal Incontinence | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03104517 | AMDC-USR (iltamiocel) | Phase 3 | Stress Urinary Incontinence | Genitourinary | Nov 2026 |
| NCT05776277 | AMDC-USR (iltamiocel) | Phase 3 | Fecal Incontinence | Gastroenterology | Dec 2026 |
No annotated target.
–
Urotronic GIE Medical Prokidney Taisho Pharmaceutical YolTech Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.